Deborah L White

Deborah L White

UNVERIFIED PROFILE

Are you Deborah L White?   Register this Author

Register author
Deborah L White

Deborah L White

Publications by authors named "Deborah L White"

Are you Deborah L White?   Register this Author

48Publications

994Reads

12Profile Views

Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy.

Leukemia 2018 10 23;32(10):2288-2291. Epub 2018 Mar 23.

Cancer Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0101-5DOI Listing
October 2018

Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients.

Cancer Lett 2018 09 4;432:69-74. Epub 2018 Jun 4.

Cancer Theme, South Australian Health & Medical Research Institute, Adelaide, SA, Australia; Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia; School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia; Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG), Australia; The Kids' Cancer Project, Australia; Australian Genomic Health Alliance (AGHA), Australia; Discipline of Paediatrics, University of Adelaide, Adelaide, SA, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2018.05.045DOI Listing
September 2018

Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression.

Br J Cancer 2018 04 13;118(7):1000-1004. Epub 2018 Mar 13.

Cancer Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0022-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931087PMC
April 2018

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression .

Oncotarget 2018 Mar 3;9(17):13423-13437. Epub 2018 Feb 3.

Cancer Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/24393
Publisher Site
http://dx.doi.org/10.18632/oncotarget.24393DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862588PMC
March 2018

Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.

Cancer Lett 2017 11 1;408:92-101. Epub 2017 Sep 1.

Cancer Theme, South Australian Health & Medical Research Institute, Adelaide, SA, Australia; Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia; Australian Genomic Health Alliance, Adelaide, SA, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03043835173052
Publisher Site
http://dx.doi.org/10.1016/j.canlet.2017.08.034DOI Listing
November 2017

A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.

Cancer Genet 2017 Oct 31;216-217:86-90. Epub 2017 Jul 31.

Cancer Theme, South Australian Health & Medical Research Institute, Adelaide, SA, Australia; Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia; Australian Genomic Health Alliance, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergen.2017.07.008DOI Listing
October 2017

A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia.

J Mol Diagn 2017 09 18;19(5):711-721. Epub 2017 Jul 18.

Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia; School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia; Australasian Leukaemia and Lymphoma Group, Melbourne, Victoria, Australia; Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, South Australia, Australia; Department of Molecular Medicine and Pathology, Flinders University and Medical Centre, Adelaide, South Australia, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2017.05.009DOI Listing
September 2017

CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.

Clin Pharmacokinet 2017 08;56(8):977-985

Discipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, 5005, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-016-0494-0DOI Listing
August 2017

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines.

PLoS One 2016 18;11(8):e0161470. Epub 2016 Aug 18.

Cancer Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0161470PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990177PMC
July 2017

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.

Blood 2017 03 3;129(9):1166-1176. Epub 2017 Jan 3.

Department of Haematology, SA Pathology, Adelaide, SA, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-10-745992DOI Listing
March 2017

KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.

Blood 2015 Dec 23;126(25):2720-3. Epub 2015 Oct 23.

Department of Haematology, SA Pathology, Adelaide, SA, Australia; School of Medicine and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-07-655589DOI Listing
December 2015

Living with CML: is death no longer the end (point)?

Blood 2015 Jul;126(1):2-4

SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE; UNIVERSITY OF ADELAIDE; AND SA PATHOLOGY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-05-644732DOI Listing
July 2015

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.

Blood 2015 Feb 17;125(6):915-23. Epub 2014 Dec 17.

Department of Haematology, and Discipline of Medicine, School of Medicine, University of Adelaide, Adelaide, Australia; Australasian Leukemia and Lymphoma Group, Melbourne, Australia; Cancer Theme, South Australia Health and Medical Research Institute, Adelaide, Australia;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-07-590315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161008PMC
February 2015

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

N Engl J Med 2014 Sep;371(11):1005-15

From the Departments of Pathology (K.G.R., D.P.-T., Y.-L.Y., K. McCastlain, G.S., J.M., S.-C.C., J.C., N.S.-M., I.I., J.W., J.R.D., C.G.M.), Computational Biology and Bioinformatics (Y.L., J.B., M.R., E.H., P.G., P.N., G.W., X.C., J.Z.), Biostatistics (D.P., C.C.), Pharmaceutical Sciences (S.W.P., M.V.R., W.E.E.), and Oncology (C.-H.P., S.J.), the Pediatric Cancer Genome Project (Y.L., L.D., C.L., M.R., J.E., J.C., K.B., R.S.F., E.H., P.G., P.N., G.W., X.C., D.Y., B.V., H.M., M.V.R., W.E.E., E.M., R.K.W., J.R.D., J.Z., C.G.M.), and Cytogenetics Shared Resource (M.V.), St. Jude Children's Research Hospital, Memphis, TN; the University of New Mexico Cancer Center and School of Medicine, Albuquerque (R.C.H., I-M.C., C.L.W.); the Genome Institute at Washington University (L.D., C.L., R.S.F., E.M., R.K.W.), the Department of Genetics, Washington University School of Medicine (L.D., C.L., R.S.F., E.M., R.K.W.), and Siteman Cancer Center, Washington University (E.M., R.K.W.) - all in St. Louis; Epidemiology and Health Policy Research, College of Medicine, University of Florida, Gainesville (M.D.); the Research Institute at Nationwide Children's Hospital (S.R., A.S., J.M.G.-F.), the Department of Pathology, College of Medicine, Ohio State University (N.A.H.), and Ohio State University Comprehensive Cancer Center (G.M., C.D.B., K. Mrózek, J.K.) - all in Columbus, OH; the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas (N.J.W.), Scott and White Hospitals and Clinics and Texas A&M Health Science Center, Temple (G.G.), the University of Texas Health Science Center San Antonio, San Antonio (M.F.-J.), and the Departments of Leukemia and Stem Cell Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (S.M.K., M.K.) - all in Texas; Maine Children's Cancer Program, Scarborough (E.C.L.); New York University Cancer Institute, New York (W.L.C.), and the Department of Medicine (Oncology), Albert Einstein

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1403088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191900PMC
September 2014

Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.

Leuk Lymphoma 2013 Mar 21;54(3):569-78. Epub 2012 Aug 21.

Division of Hematology, SA Pathology, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.715345DOI Listing
March 2013

Unraveling the "known unknowns": lessons and reflections from the new directions in leukemia research 2012 conference.

Cancer Res 2012 Sep 26;72(17):4300-3. Epub 2012 Jun 26.

Division of Haematology, Centre for Cancer Biology, University of Adelaide, Adelaide, South Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-1832DOI Listing
September 2012

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.

Leuk Lymphoma 2011 Nov 30;52(11):2139-47. Epub 2011 Jun 30.

Department of Haematology, SA Pathology, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2011.591013DOI Listing
November 2011

Predicting the response of CML patients to tyrosine kinase inhibitor therapy.

Curr Hematol Malig Rep 2011 Jun;6(2):88-95

Haematology Department, SA Pathology RAH Site, Frome Road, Adelaide, South Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-011-0087-9DOI Listing
June 2011

Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients.

Expert Rev Hematol 2011 Jun;4(3):285-99

Hematology Division, SA Pathology, Adelaide, SA 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.11.19DOI Listing
June 2011

OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

Haematologica 2011 Feb 22;96(2):213-20. Epub 2010 Oct 22.

Department of Haematology, SA Pathology (RAH Campus), Frome Road, Adelaide. Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2010.033290DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031688PMC
February 2011

Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?

Leuk Lymphoma 2011 Feb 20;52(2):165-7. Epub 2010 Dec 20.

Department of Haematology, SA Pathology (IMVS), Adelaide, Australia.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.3109/10428194.2010.54
Publisher Site
http://dx.doi.org/10.3109/10428194.2010.540362DOI Listing
February 2011

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.

J Clin Oncol 2010 Jun 26;28(16):2761-7. Epub 2010 Apr 26.

Haematology Department, Centre for Cancer Biology, SA Pathology (IMVS Campus), University of Adelaide, Frome Road, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.26.5819DOI Listing
June 2010

Predicting the response of CML patients to tyrosine kinase inhibitor therapy.

Curr Hematol Malig Rep 2009 Apr;4(2):59-65

Division of Haematology, SA Pathology IMVS/RAH Campus, Frome Road, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-009-0009-2
Publisher Site
http://dx.doi.org/10.1007/s11899-009-0009-2DOI Listing
April 2009

Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?

Authors:
Deborah L White

Leuk Lymphoma 2008 Jun;49(6):1022-3

Division of Haematology, IMVS and Hanson Institute, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1080/1042819080207463
Publisher Site
http://dx.doi.org/10.1080/10428190802074635DOI Listing
June 2008

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.

Clin Cancer Res 2008 Jun;14(12):3881-8

Division of Haematology, Institute of Medical and Veterinary Science, University of Adelaide, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-5095DOI Listing
June 2008